Gilead will pay $175 million upfront for Cell Design Labs and will dish out additional payments of up to $322 million if certain milestones are hit.
The acquisition equips Gilead with additional resources to focus on the development of CAR-T cell therapies, which are personalized medications that genetically alter patients’ immune cells to attack cancer.
Cell Design is currently working on a custom cell engineering technology, including early state treatments for prostate cancer, which Gilead hopes to capitalize on.
More articles on supply chain:
Prescription drug spending slows in 2016: 5 things to know
Worsening IV fluid shortage forces New York hospital to transfer patient
FDA urges drugmaker to recall osteoarthritis product following liver and lung injury reports
